Urokinase, CX3CL1, CCL2, TRAIL and IL-18 induced by interferon-β treatment.

Christina ZhukovskyStephanie HermanAnna WibergJanet L CunninghamKim KultimaJoachim Burman

Published in: Acta neurologica Scandinavica (2021)

CCL2 and TRAIL were confirmed to be modulated with interferon beta treatment in MS. As novel findings, we now report that uPA and CX3CL1 were differentially expressed in MS and increased after IFN-beta-1a treatment. Conflicting results have been reported on how interferon beta affects IL-18.

Keyphrases

dendritic cells
mass spectrometry
multiple sclerosis
immune response
ms ms
liver fibrosis